The 2022 ICD-10-CM files below contain information on the ICD-10-CM updates for FY 2022. These 2022 ICD-10-CM codes are to be used for discharges occurring from October 1, 2021, through September 30, 2022, and for patient encounters occurring from October 1, 2021, through September 30, 2022.
Total changes - 243
- New Codes - 191 Additions
- Deleted Codes - 25 Deletions
- Revised Codes - 27 Revisions
NEW CODE EFFECTIVE FROM OCTOBER 1ST, 2021 TO SEPTEMBER 30, 2022
Code Description
A79.82 Anaplasmosis [A. phagocytophilum]
C56.3 Malignant neoplasm of bilateral ovaries
C79.63 Secondary malignant neoplasm of bilateral ovaries
C84.7A Anaplastic large cell lymphoma, ALK-negative, breast
D55.21 Anemia due to pyruvate kinase deficiency
D55.29 Anemia due to other disorders of glycolytic enzymes
D75.83 Thrombocytosis
D75.838 Other thrombocytosis
D75.839 Thrombocytosis, unspecified
D89.44 Hereditary alpha tryptasemia
E75.244 Niemann-Pick disease type A/B
F32.A Depression, unspecified
F78.A Other genetic related intellectual disabilities
F78.A1 SYNGAP1-related intellectual disability
F78.A9 Other genetic related intellectual disability
G04.82 Acute flaccid myelitis
G44.86 Cervicogenic headache
G92.00 Immune effector cell-associated neurotoxicity syndrome, grade unspecified
G92.01 Immune effector cell-associated neurotoxicity syndrome, grade 1
G92.02 Immune effector cell-associated neurotoxicity syndrome, grade 2
G92.03 Immune effector cell-associated neurotoxicity syndrome, grade 3
G92.04 Immune effector cell-associated neurotoxicity syndrome, grade 4
G92.05 Immune effector cell-associated neurotoxicity syndrome, grade 5
G92.8 Other toxic encephalopathy
G92.9 Unspecified toxic encephalopathy
I5A Non-ischemic myocardial injury (non-traumatic)
K22.81 Esophageal polyp
K22.82 Esophagogastric junction polyp
K22.89 Other specified disease of esophagus
K31.A0 Gastric intestinal metaplasia, unspecified
K31.A11 Gastric intestinal metaplasia without dysplasia, involving the antrum
K31.A12 Gastric intestinal metaplasia without dysplasia, involving the body (corpus)
K31.A13 Gastric intestinal metaplasia without dysplasia, involving the fundus
K31.A14 Gastric intestinal metaplasia without dysplasia, involving the cardia
K31.A15 Gastric intestinal metaplasia without dysplasia, involving multiple sites
K31.A19 Gastric intestinal metaplasia without dysplasia, unspecified site
K31.A21 Gastric intestinal metaplasia with low grade dysplasia
K31.A22 Gastric intestinal metaplasia with high grade dysplasia
K31.A29 Gastric intestinal metaplasia with dysplasia, unspecified
L24.A0 Irritant contact dermatitis due to friction or contact with body fluids, unspecified
L24.A1 Irritant contact dermatitis due to saliva
L24.A2 Irritant contact dermatitis due to fecal, urinary or dual incontinence
L24.A9 Irritant contact dermatitis due friction or contact with other specified body fluids
L24.B0 Irritant contact dermatitis related to unspecified stoma or fistula
L24.B1 Irritant contact dermatitis related to digestive stoma or fistula
L24.B2 Irritant contact dermatitis related to respiratory stoma or fistula
L24.B3 Irritant contact dermatitis related to fecal or urinary stoma or fistula
M31.10 Thrombotic microangiopathy, unspecified
M31.11 Hematopoietic stem cell transplantation-associated thrombotic microangiopathy [HSCT-TMA]
M31.19 Other thrombotic microangiopathy
M35.05 Sjogren syndrome with inflammatory arthritis
M35.06 Sjogren syndrome with peripheral nervous system involvement
M35.07 Sjogren syndrome with central nervous system involvement
M35.08 Sjogren syndrome with gastrointestinal involvement
M35.0A Sjogren syndrome with glomerular disease
M35.0B Sjogren syndrome with vasculitis
M35.0C Sjogren syndrome with dental involvement
M45.A0 Non-radiographic axial spondyloarthritis of unspecified sites in spine
M45.A1 Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region
M45.A2 Non-radiographic axial spondyloarthritis of cervical region
M45.A3 Non-radiographic axial spondyloarthritis of cervicothoracic region
M45.A4 Non-radiographic axial spondyloarthritis of thoracic region
M45.A5 Non-radiographic axial spondyloarthritis of thoracolumbar region
M45.A6 Non-radiographic axial spondyloarthritis of lumbar region
M45.A7 Non-radiographic axial spondyloarthritis of lumbosacral region
M45.A8 Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region
M45.AB Non-radiographic axial spondyloarthritis of multiple sites in spine
M54.50 Low back pain, unspecified
M54.51 Vertebrogenic low back pain
M54.59 Other low back pain
P00.82 Newborn affected by (positive) maternal group B streptococcus (GBS) colonization
P09.1 Abnormal findings on neonatal screening for inborn errors of metabolism
P09.2 Abnormal findings on neonatal screening for congenital endocrine disease
P09.3 Abnormal findings on neonatal screening for congenital hematologic disorders
P09.4 Abnormal findings on neonatal screening for cystic fibrosis
P09.5 Abnormal findings on neonatal screening for critical congenital heart disease
P09.6 Abnormal findings on neonatal screening for neonatal hearing loss
P09.8 Other abnormal findings on neonatal screening
P09.9 Abnormal findings on neonatal screening, unspecified
R05.1 Acute cough
R05.2 Sub acute cough
R05.3 Chronic cough
R05.4 Cough syncope
R05.8 Other specified cough
R05.9 Cough, unspecified
R35.81 Nocturnal polyuria
R35.89 Other polyuria
R45.88 Non-suicidal self-harm
R63.30 Feeding difficulties, unspecified
R63.31 Pediatric feeding disorder, acute
R63.32 Pediatric feeding disorder, chronic
R63.39 Other feeding difficulties
R79.83 Abnormal findings of blood amino-acid level
S06.A0XA Traumatic brain compression without herniation, initial encounter
S06.A0XD Traumatic brain compression without herniation, subsequent encounter
S06.A0XS Traumatic brain compression without herniation, sequela
S06.A1XA Traumatic brain compression with herniation, initial encounter
S06.A1XD Traumatic brain compression with herniation, subsequent encounter
S06.A1XS Traumatic brain compression with herniation, sequela
T40.711A Poisoning by cannabis, accidental (unintentional), initial encounter
T40.711D Poisoning by cannabis, accidental (unintentional), subsequent encounter
T40.711S Poisoning by cannabis, accidental (unintentional), sequela
T40.712A Poisoning by cannabis, intentional self-harm, initial encounter
T40.712D Poisoning by cannabis, intentional self-harm, subsequent encounter
T40.712S Poisoning by cannabis, intentional self-harm, sequela
T40.713A Poisoning by cannabis, assault, initial encounter
T40.713D Poisoning by cannabis, assault, subsequent encounter
T40.713S Poisoning by cannabis, assault, sequela
T40.714A Poisoning by cannabis, undetermined, initial encounter
T40.714D Poisoning by cannabis, undetermined, subsequent encounter
T40.714S Poisoning by cannabis, undetermined, sequela
T40.715A Adverse effect of cannabis, initial encounter
T40.715D Adverse effect of cannabis, subsequent encounter
T40.715S Adverse effect of cannabis, sequela
T40.716A Underdosing of cannabis, initial encounter
T40.716D Underdosing of cannabis, subsequent encounter
T40.716S Underdosing of cannabis, sequela
T40.721A Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter
T40.721D Poisoning by synthetic cannabinoids, accidental (unintentional), subsequent encounter
T40.721S Poisoning by synthetic cannabinoids, accidental (unintentional), sequela
T40.722A Poisoning by synthetic cannabinoids, intentional self-harm, initial encounter
T40.722D Poisoning by synthetic cannabinoids, intentional self-harm, subsequent encounter
T40.722S Poisoning by synthetic cannabinoids, intentional self-harm, sequela
T40.723A Poisoning by synthetic cannabinoids, assault, initial encounter
T40.723D Poisoning by synthetic cannabinoids, assault, subsequent encounter
T40.723S Poisoning by synthetic cannabinoids, assault, sequela
T40.724A Poisoning by synthetic cannabinoids, undetermined, initial encounter
T40.724D Poisoning by synthetic cannabinoids, undetermined, subsequent encounter
T40.724S Poisoning by synthetic cannabinoids, undetermined, sequela
T40.725A Adverse effect of synthetic cannabinoids, initial encounter
T40.725D Adverse effect of synthetic cannabinoids, subsequent encounter
T40.725S Adverse effect of synthetic cannabinoids, sequela
T40.726A Underdosing of synthetic cannabinoids, initial encounter
T40.726D Underdosing of synthetic cannabinoids, subsequent encounter
T40.726S Underdosing of synthetic cannabinoids, sequela
T80.82XA Complication of immune effector cellular therapy, initial encounter
T80.82XD Complication of immune effector cellular therapy, subsequent encounter
T80.82XS Complication of immune effector cellular therapy, sequela
U09.9 Post COVID-19 condition, unspecified
Y35.899A Legal intervention involving other specified means, unspecified person injured, initial encounter
Y35.899D Legal intervention involving other specified means, unspecified person injured, subsequent encounter
Y35.899S Legal intervention involving other specified means, unspecified person injured, sequela
Z55.5 Less than a high school diploma
Z58.6 Inadequate drinking-water supply
Z59.00 Homelessness unspecified
Z59.01 Sheltered homelessness
Z59.02 Unsheltered homelessness
Z59.41 Food insecurity
Z59.48 Other specified lack of adequate food
Z59.81 Housing instability, housed
Z59.811 Housing instability, housed, with risk of homelessness
Z59.812 Housing instability, housed, homelessness in past 12 months
Z59.819 Housing instability, housed unspecified
Z59.89 Other problems related to housing and economic circumstances
Z71.85 Encounter for immunization safety counseling
Z91.014 Allergy to mammalian meats
Z91.51 Personal history of suicidal behavior
Z91.52 Personal history of nonsuicidal self-harm
Z92.85 Personal history of cellular therapy
Z92.850 Personal history of Chimeric Antigen Receptor T-cell therapy
Z92.858 Personal history of other cellular therapy
Z92.859 Personal history of cellular therapy, unspecified
Z92.86 Personal history of gene therapy
No comments:
Post a Comment